What is the recommended empiric in-patient (non-ICU) therapy for community-acquired pneumonia without MDR risk?

• A. Macrolide alone.
• B. Tetracycline alone.
• C. A beta-lactam plus a macrolide or a respiratory fluoroquinolone as monotherapy.
• D. Vancomycin plus piperacillin-tazobactam.

Answer: (C)

Covering both typical bacteria (like Streptococcus pneumoniae and Haemophilus influenzae) and atypical pathogens (such as Mycoplasma and Legionella) is the aim of empiric therapy for inpatient, non-ICU community-acquired pneumonia without MDR risk. The best approach is either a beta-lactam given with a macrolide to provide dual coverage, or a respiratory fluoroquinolone used as monotherapy, which offers broad activity against both typical and atypical organisms. This strategy targets the common pathogens effectively while avoiding unnecessary broad-spectrum coverage.

Choosing a macrolide alone isn’t ideal for hospitalized patients because it may not reliably cover typical bacteria at the disease’s severity. A tetracycline alone also isn’t considered sufficient monotherapy for hospital-level CAP. Reserving vancomycin plus piperacillin-tazobactam is for severe CAP or when MDR pathogens are suspected, not for CAP without MDR risk.